Allied Academics Publication is an amalgamation of a few regarded scholarly and logical affiliations known for advancing logical demeanor. Set up in the year 1997, Andrew John Publishing Group is a specific Medical distributer that works as a team with the affiliation and social orders. This distributing house has been based on the base of regarded scholastic and research establishments including The College of Audiologists and Speech Language Pathologists of Ontario(CASLPO), The Association for Public Safety Communications Officials of Canada (APCO), The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM).
Allied Academics invites all the participants from all over the world to attend "18th International Vaccine Adjuvants and Delivery Technologies” surrounding the theme “Discussion on latest research and technologies in Vaccine adjuvants & delivery systems”, Going to be held in October 30-31, 2017 in Chicago, USA which includes prompt keynote presentations, oral talks, poster presentations and exhibitions.
We are looking forward to your active participation in this very important International Conference on Vaccine
Allied Academies formally invites you to attend the Vaccine Delivery 2017 which will be held in Chicago, USA amid October 30-31 2017. Vaccine Delivery 2017 will focus on the latest and stimulating progressions in vaccine and technologies related to it. Vaccine Delivery 2017 offering an open entryway for the scientists, researchers all over the globe to meet, discus and see new advancements.
Theme: “Discussion on latest research and technologies in Vaccine adjuvants & delivery systems"
Vaccine Delivery 2017 event will include expert presentations, keynote talks, plenary lectures, Entrepreneurs Investment meet, B2B Meetings, Scientific networking etc. where you can have an opportunity to display/talk about your research achievements and contradictions in front of World-class experts, budding scientists & delegates who are gathering from reputed universities and organizations across the globe.
18th International Conference on Vaccine Adjuvants and Delivery Technologies to be held during October 30-31, 2017 at Chicago, USA with the theme “Discussion on latest research and technologies in Vaccine adjuvants & delivery systems.”
The goal of vaccination is the generation of a strong immune response to the administered antigen able to provide long-term protection against infection and the adjuvant is a substance that is added to a vaccine to increase the body's immune response to the vaccine. The problem with pure recombinant or synthetic antigens used in modern day vaccines is that they are generally far less immunogenic than older style live or killed whole organism vaccines. This has created a major need for improved and more powerful adjuvants for use in these vaccines. Vaccines containing adjuvants are tested for safety in clinical trials before they are licensed for use in the United States, and they are continuously monitored by CDC and FDA. Newer and more expensive vaccine adjuvants are coming into the market faster than ever before.
The reasons driving the development of vaccines as controlled drug delivery systems are as follows:
- Immunization failure with conventional immunization regimen involving prime doses and booster doses, as patients neglect the latter.
Vaccines delivery technology on the other hand:
- Allow for the incorporation of doses of antigens so that booster doses are no longer necessary as antigens are released slowly in a controlled manner.
- Control the spatial and temporal presentation of antigens to the immune system there by promoting their targeting straight to the immune cells.
Recent advances across a wide range of scientific disciplines have enhanced the prospects for developing new and better vaccine adjuvants and delivery technologies. Various pharmaceutical companies are working to develop novel vaccines for diseases such as lung cancer, breast cancer, Alzheimer, etc. These include the application of new technologies such as molecular biology to vaccine research, advances in our understanding of the immune system. Vaccine Delivery 2017 a mass all the extroverts under one roof of current advances.
1. Vaccine Adjuvant
2. Vaccine Delivery
3. Vaccine Adjuvants- FDA & CDC
4. Vaccines Adjuvants Market Analysis
5. Biomarkers of Vaccine Adjuvant Potency and Safety
6. Nanotechnology in Vaccine Delivery System
7. Novel Vaccines Against Infectious Diseases
8. Veterinary Vaccines and Their Delivery Systems
9. Advances in Vaccine Technology
10. Vaccine Design, Production and Safety
11. Vaccine Development
12. Human Genetics and Vaccines
13. Vaccine Safety Monitoring
14. Vaccines Against Infectious Diseases and Cancer
Importance & Scope:
18th International Conference on Vaccine Adjuvants and Delivery Technologies main aim is to bring together leading academic scientists, researchers, business delegates, research scholars and student communities to exchange and share their experiences and research results about all aspects of Vaccine Adjuvants and Delivery Technologies. It also provides the chance to present and discuss about the most recent trends in the innovation of new vaccine adjuvants and delivery technologies and also their requirement. It is an international platform for the research about vaccines and the development of new vaccine adjuvants and delivery technologies and exchanging views about it.
Vaccine Delivery 2017 Targets, CEO’s, Directors, Scientists, Professors, Students of all Biotech & Pharmaceutical companies, Universities and colleges globally.
Major Hospitals in USA:
Massachusetts General Hospital, Boston
Mayo Clinic, Rochester, Minnesota
Johns Hopkins Hospital, Baltimore (Tie)
UCLA Medical Centre, Los Angeles (Tie)
Brigham and Women's Hospital, Boston
Major Hospitals around the World:
Johns Hopkins Hospital Baltimore U.S
Chris Hani Baragwanath Hospital Johannesburg South Africa
Stanford Hospitals and Clinics U.S
Great Ormond Street Hospital London UK
Major Universities in USA:
Harvard Medical School
UCSF School of Medicine
David Geffen School of Medicine
UNC School of Medicine
Pittsburgh School of Medicine
Stanford School of Medicine
Pritzker School of Medicine
Major Universities around the World:
University of Oxford
University of Cambridge
Johns Hopkins University
University of California, San Francisco
University of California, Los Angeles (UCLA)
National University of Singapore (NUS)
Major Associations and Societies in USA:
National Cancer Institute
Advisory Committee on Immunization Practices (ACIP)
Advisory Commission on Childhood Vaccines
Vaccines and Related Biological Products Advisory Committee
American Pharmacists Association
American Medical Association
American Society for Microbiology Office of Education and Training
Top 10 pharmaceutical companies based on global vaccine revenue market share in 2014 and 2020:
This statistic displays the top 10 global pharmaceutical companies based on their vaccine revenue market share worldwide in 2014, and a projection for 2020. Pfizer is expected to account for nearly 21% of the global vaccine market share by 2020, largely due to success with its pneumococcal vaccine, Prevnar 13. A vaccine often contains an agent that is made from a weakened form of a disease microbe, that is then used to stimulate the body's immune system to destroy and recognize the microorganism in case of later exposures.
Global Market Analysis of Vaccines
The global vaccines market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a growth rate of 11.8% from 2014 to 2019.
From global pharmaceutical market sale vaccines occupied very small size of market 2/3% but there is spectacular growth rate 10-15% per year when compare to pharmaceuticals which was 5-7% only. Tripled in value from USD 5B in 2000 to almost USD 24 B in 2013.
Influenza vaccine market: estimated at $2.9 billion in 2011 to $3.8 billion by 2018 whereas US market: $1.6 billion in 2011 to $2.2 billion in 2018.
Global market projected to rise to USD 100 B by 2025; More than 120 new products in the development pipeline and 60 are of importance for developing countries
Wide licensing and registration of new and innovative vaccines Increased presence of sale forces and MNC representatives: pharm like model.